Alto Neuroscience, Inc. $ANRO is Peapod Lane Capital LLC’s 3rd Largest Position

Peapod Lane Capital LLC lowered its position in Alto Neuroscience, Inc. (NYSE:ANRO) by 9.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 253,992 shares of the company’s stock after selling 27,971 shares during the quarter. Alto Neuroscience comprises 3.8% of Peapod Lane Capital LLC’s investment portfolio, making the stock its 3rd largest holding. Peapod Lane Capital LLC owned approximately 0.82% of Alto Neuroscience worth $4,521,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Armistice Capital LLC increased its holdings in Alto Neuroscience by 0.7% in the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after acquiring an additional 12,000 shares during the last quarter. Vanguard Group Inc. increased its holdings in Alto Neuroscience by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock worth $4,444,000 after acquiring an additional 20,702 shares during the last quarter. Marshall Wace LLP increased its holdings in Alto Neuroscience by 9.9% in the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after acquiring an additional 84,417 shares during the last quarter. Millennium Management LLC increased its holdings in Alto Neuroscience by 4.3% in the 3rd quarter. Millennium Management LLC now owns 315,758 shares of the company’s stock worth $1,269,000 after acquiring an additional 12,896 shares during the last quarter. Finally, Susquehanna International Group LLP increased its holdings in Alto Neuroscience by 154.9% in the 3rd quarter. Susquehanna International Group LLP now owns 155,676 shares of the company’s stock worth $626,000 after acquiring an additional 94,613 shares during the last quarter.

Alto Neuroscience Stock Down 5.5%

Shares of NYSE ANRO opened at $25.67 on Friday. Alto Neuroscience, Inc. has a 52 week low of $2.12 and a 52 week high of $28.44. The business has a 50-day simple moving average of $21.76 and a two-hundred day simple moving average of $16.80. The company has a quick ratio of 15.69, a current ratio of 15.69 and a debt-to-equity ratio of 0.12. The company has a market cap of $820.16 million, a P/E ratio of -11.78 and a beta of 2.01.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Monday, March 16th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.11. Research analysts anticipate that Alto Neuroscience, Inc. will post -2.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ANRO shares. Robert W. Baird decreased their price objective on Alto Neuroscience from $41.00 to $38.00 and set an “outperform” rating for the company in a report on Thursday, April 2nd. BTIG Research lifted their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. JonesTrading decreased their price objective on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price objective on shares of Alto Neuroscience in a report on Monday, March 16th. Finally, Wedbush decreased their price objective on Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating for the company in a report on Thursday, April 2nd. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $35.14.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.